

## A Novel PAFAH1B1 Splicing Variant Identified in a Patient with Classical Lissencephaly

メタデータ	言語: eng 出版者: 公開日: 2021-02-02 キーワード (Ja): キーワード (En): 作成者: YANAGISHITA, Tomoe, ETO, Kaoru, YAMAMOTO-SHIMOJIMA, Keiko, IMAIZUMI, Taichi, NAGATA, Satoru, YAMAMOTO, Toshiyuki メールアドレス: 所属:
URL	<a href="http://hdl.handle.net/10470/00032751">http://hdl.handle.net/10470/00032751</a>

## A Novel *PAFAH1B1* Splicing Variant Identified in a Patient with Classical Lissencephaly

Tomoe Yanagishita,<sup>1,2</sup> Kaoru Eto,<sup>1</sup> Keiko Yamamoto-Shimajima,<sup>1,2</sup>  
Taichi Imaizumi,<sup>2,3</sup> Satoru Nagata,<sup>1</sup> and Toshiyuki Yamamoto<sup>1,2</sup>

<sup>1</sup>Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan

<sup>2</sup>Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan

<sup>3</sup>Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan

(Accepted June 30, 2020)

(Advance Publication by J-STAGE August 27, 2020)

Lissencephaly is a severe brain malformation associated with abnormal formation of cerebral sulci. Until now, many genes related to lissencephaly have been identified. Among them, classical lissencephaly has been often related to the platelet activating factor acetylhydrolase 1B regulatory subunit 1 gene (*PAFAH1B1*). We identified a novel *PAFAH1B1* splicing variant (NM\_000430.3:c.118-2A>G) in a female patient with classical lissencephaly manifesting as developmental delay, growth failure, and epilepsy. This variant was not detected in her parents, indicating de novo occurrence of the variant in the patient. To confirm whether this variant is in fact related to splicing error, RNA expression was analyzed. As suspected, an abnormal short band excluding exon 4 was additionally detected. This evidence confirmed that the novel variant is definitely pathogenic to cause lissencephaly in the patient.

**Key Words:** agyria, West syndrome, Miller-Dieker syndrome

### Introduction

Lissencephaly is one of the malformations of the brain, which manifests as abnormal formation of cerebral sulci. Through radiological examination using magnetic resonance imaging (MRI), lissencephaly has been classified into several types, including agyria, pachygyria, and subcortical band heterotopia.<sup>1</sup> These radiological classifications are related to genetic classifications. Miller-Dieker syndrome has been established as one of the congenital malformation syndromes and it has been related to the


subtelomeric deletion of 17p.<sup>2</sup> Patients with Miller-Dieker syndrome (MIM #247200) show classical lissencephaly and facial dysmorphism. Thus, genes related to these clinical features had been suspected to be localized in 17p. In 1993, the platelet activating factor acetylhydrolase 1B regulatory subunit 1 gene (*PAFAH1B1*; former name *LIS1*) located on 17p was isolated as the gene responsible for lissencephaly.<sup>3</sup> Later, the tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon gene (*YWHAE*), which is located more towards the telomeric region and at a distance from *PA-*

---

Corresponding Author: Toshiyuki Yamamoto, Institute of Medical Genetics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. yamamoto.toshiyuki@twmu.ac.jp

doi: 10.24488/twmuj.2020003

Copyright © 2020 Society of Tokyo Women's Medical University. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.



**Figure 1** Brain magnetic resonance imaging of the patient. (A) An axial T1-weight image shows agyria and thick cortical surface. (B) A sagittal T1-weighted image shows reduced volume of the brain.

*FAH1B1*, was identified as the gene related to facial dysmorphism.<sup>4</sup>

Recently developed equipments for genomic analysis have promoted the understanding of the genomic basis of lissencephaly. Many genes, including the reelin (*RELN*), the tubulin alpha 1a (*TUBA1A*), and the doublecortin (*DCX*) genes, have been identified as the genes responsible for brain malformation. Intriguingly, *PAFAH1B1*-associated lissencephaly, included in Online Mendelian Inheritance in Man<sup>®</sup> (<https://omim.org/>) as an autosomal dominant disease of Lissencephaly 1 (MIM #607432), accounts for majority of the cases (40%) in lissencephaly cohorts.<sup>5,6</sup> Consequently, many disease-causing nucleotide variants of *PAFAH1B1* have been reported.<sup>7,8</sup>

Here, we have identified a novel disease-causing variant of *PAFAH1B1* in a patient with classical lissencephaly. As the identified variant was located on the splicing acceptor site, abnormal splicing pattern was confirmed by molecular analysis.


### Case Report

A 4-month-old girl was born at 39 weeks and 5 days of gestation with birth weight of 2,370 g, height of 42.6 cm, and occipitofrontal circumference (OFC) of 31.7 cm. Apgar score was 7/9, indicating that there was no asphyxia at birth. Because dilatation of bilateral ventricles had been suggested after fetal ultrasound at 36 weeks of gestation, the girl was admitted to neonatal

intensive care unit at birth. On 6th day after delivery, brain magnetic resonance imaging (MRI) revealed lissencephaly associated with no gyrus formation on the surface of the cerebrum (**Figure 1**). After discharge from the hospital, she started to show myoclonus-like movements. Although phenobarbital was prescribed for several weeks, she began to suffer from series of epileptic spasms and admitted to our hospital when she was months old.

At the time of admission, her height was 55.5 cm ( $-4.0$  SD), weight was 4.9 kg ( $-2.4$  SD), and OFC was 37.0 cm ( $-3.1$  SD), indicating growth failure and microcephaly. There was no dysmorphic finding. Vital signs were within normal limit. On neurological examination, generalized hypotonia was noted because of which she had poor head control. Routine laboratory examination showed no abnormality; however, electroencephalogram revealed atypical hypsarrhythmia (**Figure 2**), indicating West syndrome. Hence, the girl was started on adrenocorticotrophic hormone therapy.

For precise diagnosis, genetic diagnosis was performed. Fluorescence in-situ hybridization (FISH) showed no deletion in the 17p13.3 region, which is responsible for Miller-Dieker syndrome. Thus, comprehensive genomic analysis was performed. After obtaining written informed consent from her parents, peripheral blood samples were collected from the patient and her parents. This study was performed in accordance with the Declaration of Helsinki and was approved by the



**Figure 2** Electroencephalogram. Atypical hypsarrhythmia with high voltage wave bursts is shown.


Gene Analysis Research Ethics Committee of Tokyo Women's Medical University (No. 341B). Genomic DNA was extracted from the blood samples using a QIAamp DNA extraction kit (Qiagen, Hilden, Germany). Next-generation sequencing (NGS) was performed to screen single-nucleotide variants using TruSight One ver 1.0 sequencing panel (Illumina, San Diego, CA, USA) as described previously.<sup>9</sup> The extracted data were mapped to a reference genome (GRCh37/hg19) using the BWA Enrichment ver 1.0 cloud software (Illumina), and annotated and filtered using the Variant Studio software (Illumina).

After filtering the data, a novel heterozygous variant was detected in the splicing acceptor site of exon 4 of *PAFAH1B1* (NM\_000430.3:c.118-2A>G). There was no possible candidate variant in other genes related to lissencephaly. Sanger sequencing confirmed the existence of this variant in the patient but not in her parents (**Figure 3A**). This indicated de novo occurrence of the variant. To further confirm whether this variant did in fact cause the splicing abnormality, expressed RNA was examined. Total RNA extracted from Epstein-Barr virus-transformed leukocytes was reverse-transcribed

(RT) into complementary DNA (cDNA). The cDNA was amplified by RT-PCR as described previously.<sup>10</sup> The result showed the presence of an abnormal short band in addition to the normal band (**Figure 3B**). By use of DNA extraction kit (Qiagen), DNA amplicons were extracted through separated bands of both a normal- and an abnormal short band. Sanger sequencing performed using the extracted DNA samples confirmed exon 4 skipping (**Figure 3C**).

## Discussion

In this study, we reported a patient with classical lissencephaly. The patient presented with developmental delay, hypotonia, and epileptic spasms. These clinical findings were typical of the clinical course of lissencephaly. According to the previously proposed classification of classic lissencephaly, brain MRI findings of this patient were considered as grade 1.<sup>11</sup> From this radiological pattern, *PAFAH1B1* located on 17p was suspected as the most possible candidate gene.<sup>12</sup> However, chromosomal deletion involving 17p was dismissed based on the results of FISH. *PAFAH1B1*



**Figure 3** Results of molecular analyses. (A) Genomic sequence for the patient shows a nucleotide alteration (a>g) in the splicing acceptor site of exon 4, whereas control shows the wild type sequence. (B) Electrophoresis of the amplicons obtained after reverse transcribed (RT)-PCR revealed an additional short band (Band 2) in addition to the normal band (Band 1) in the patient. (C) Sanger sequence for Band 2 confirmed exon 4 skipping, whereas Band 1 (expected to be derived from the normal allele) showed normal pattern.

consists of as many as 10 exons and there are more than 10 possible candidate genes of lissencephaly other than *PAFAH1B1*. Thus, comprehensive genomic analysis using TruSight One was considered as a more efficient way for examining the status of candidate genes than targeted Sanger sequencing.

As suspected, a de novo variant was identified in *PAFAH1B1*. Splice variants are rare in *PAFAH1B1*.<sup>13</sup> We confirmed exon skipping by RT-PCR and subsequent Sanger sequencing. The exon 4 that was deleted in the patient consists of multiples of three nucleotides. Thus, exon 4 skipping was predicted to cause in-frame deletion and not frame-shift deletion. Generally, frameshift leads to premature termination and subsequent nonsense-mediated mRNA decay. Thus, frameshift variants are usually related to loss-of-function and most of the variants identified in *PAFAH1B1* are related to loss-of-function.<sup>13</sup> In comparison, in-frame deletions are

generally related to milder phenotypes in genetic disorders; however, in this case, exon 4 encodes an important coiled-coil domain, which binds to microtubule-associated binding proteins.<sup>14,15</sup> Therefore, exon 4 skipping was considered to be related to loss-of-function mechanism.

### Acknowledgements

The authors would like to express gratitude for the patient and her family for their cooperation. This work was supported by JSPS KAKENHI JP18K07803 (TY).

**Conflicts of Interest:** There is no conflict of interest for any of the authors.

### References

1. Di Donato N, Chiari S, Mirzaa GM et al: Lissencephaly:



- Expanded imaging and clinical classification. *Am J Med Genet A* 173: 1473–1488, 2017
2. Shimojima K, Sugiura C, Takahashi H et al: Genomic copy number variations at 17p13.3 and epileptogenesis. *Epilepsy Res* 89: 303–309, 2010
  3. Reiner O, Carrozzo R, Shen Y et al: Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats. *Nature* 364: 717–721, 1993
  4. Schiff M, Delahaye A, Andrieux J et al: Further delineation of the 17p13.3 microdeletion involving YWHAE but distal to PAFAH1B1: four additional patients. *Eur J Med Genet* 53: 303–308, 2010
  5. Di Donato N, Timms AE, Aldinger KA et al: Analysis of 17 genes detects mutations in 81% of 811 patients with lissencephaly. *Genet Med* 20: 1354–1364, 2018
  6. Parrini E, Conti V, Dobyns WB et al: Genetic Basis of Brain Malformations. *Mol Syndromol* 7: 220–233, 2016
  7. Saillour Y, Carion N, Quelin C et al: LIS1-related isolated lissencephaly: spectrum of mutations and relationships with malformation severity. *Arch Neurol* 66: 1007–1015, 2009
  8. Uyanik G, Morris-Rosendahl DJ, Stiegler J et al: Location and type of mutation in the LIS1 gene do not predict phenotypic severity. *Neurology* 69: 442–447, 2007
  9. Yamamoto T, Imaizumi T, Yamamoto-Shimojima K et al: Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disorders. *Brain Dev* 41: 776–782, 2019
  10. Yamamoto-Shimojima K, Imaizumi T, Aoki Y et al: Elucidation of the pathogenic mechanism and potential treatment strategy for a female patient with spastic paraplegia derived from a single-nucleotide deletion in PLP1. *J Hum Genet* 64: 665–671, 2019
  11. Dobyns WB, Truwit CL: Lissencephaly and other malformations of cortical development: 1995 update. *Neuropediatrics* 26: 132–147, 1995
  12. Tan AP, Chong WK, Mankad K: Comprehensive genotype-phenotype correlation in lissencephaly. *Quant Imaging Med Surg* 8: 673–693, 2018
  13. Philbert M, Maillard C, Cavallin M et al: A novel recurrent LIS1 splice site mutation in classic lissencephaly. *Am J Med Genet A* 173: 561–564, 2017
  14. Kim MH, Cooper DR, Oleksy A et al: The structure of the N-terminal domain of the product of the lissencephaly gene Lis1 and its functional implications. *Structure* 12: 987–998, 2004
  15. Jiménez-Mateos EM, Wandosell F, Reiner O et al: Binding of microtubule-associated protein 1B to LIS1 affects the interaction between dynein and LIS1. *Biochem J* 389: 333–341, 2005